322 related articles for article (PubMed ID: 11772127)
1. Renal toxicity with sevoflurane: a storm in a teacup?
Gentz BA; Malan TP
Drugs; 2001; 61(15):2155-62. PubMed ID: 11772127
[TBL] [Abstract][Full Text] [Related]
2. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
Kharasch ED; Frink EJ; Zager R; Bowdle TA; Artru A; Nogami WM
Anesthesiology; 1997 Jun; 86(6):1238-53. PubMed ID: 9197292
[TBL] [Abstract][Full Text] [Related]
3. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers.
Eger EI; Gong D; Koblin DD; Bowland T; Ionescu P; Laster MJ; Weiskopf RB
Anesth Analg; 1997 Nov; 85(5):1154-63. PubMed ID: 9356118
[TBL] [Abstract][Full Text] [Related]
4. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
Kharasch ED; Thorning D; Garton K; Hankins DC; Kilty CG
Anesthesiology; 1997 Jan; 86(1):160-71. PubMed ID: 9009951
[TBL] [Abstract][Full Text] [Related]
5. Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers.
Goldberg ME; Cantillo J; Gratz I; Deal E; Vekeman D; McDougall R; Afshar M; Zafeiridis A; Larijani G
Anesth Analg; 1999 Feb; 88(2):437-45. PubMed ID: 9972771
[TBL] [Abstract][Full Text] [Related]
6. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
Kharasch ED; Jubert C
Anesthesiology; 1999 Nov; 91(5):1267-78. PubMed ID: 10551576
[TBL] [Abstract][Full Text] [Related]
7. P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product.
Kharasch ED; Hankins DC
Drug Metab Dispos; 1996 Jun; 24(6):649-54. PubMed ID: 8781780
[TBL] [Abstract][Full Text] [Related]
8. Effects of probenecid on renal function in surgical patients anesthetized with low-flow sevoflurane.
Higuchi H; Wada H; Usui Y; Goto K; Kanno M; Satoh T
Anesthesiology; 2001 Jan; 94(1):21-31. PubMed ID: 11135718
[TBL] [Abstract][Full Text] [Related]
9. [Compound A: toxicology and clinical relevance].
Kharasch ED
Anaesthesist; 1998 Nov; 47 Suppl 1():S7-10. PubMed ID: 9893874
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
Gul Altuntas T; Kharasch ED
Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
Altuntas TG; Zager RA; Kharasch ED
Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat.
Martin JL; Laster MJ; Kandel L; Kerschmann RL; Reed GF; Eger EI
Anesth Analg; 1996 Apr; 82(4):770-4. PubMed ID: 8615496
[TBL] [Abstract][Full Text] [Related]
13. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers.
Ebert TJ; Messana LD; Uhrich TD; Staacke TS
Anesth Analg; 1998 Mar; 86(3):662-7. PubMed ID: 9495434
[TBL] [Abstract][Full Text] [Related]
14. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
Ebert TJ; Frink EJ; Kharasch ED
Anesthesiology; 1998 Mar; 88(3):601-10. PubMed ID: 9523801
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED
Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151
[TBL] [Abstract][Full Text] [Related]
16. Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
Eger EI; Ionescu P; Laster MJ; Gong D; Weiskopf RB; Kerschmann RL
Anesth Analg; 1997 Nov; 85(5):1164-70. PubMed ID: 9356119
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers.
Eger EI; Koblin DD; Bowland T; Ionescu P; Laster MJ; Fang Z; Gong D; Sonner J; Weiskopf RB
Anesth Analg; 1997 Jan; 84(1):160-8. PubMed ID: 8989018
[TBL] [Abstract][Full Text] [Related]
18. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
[TBL] [Abstract][Full Text] [Related]
19. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
[TBL] [Abstract][Full Text] [Related]
20. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
Spracklin DK; Kharasch ED
Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
